Abstract
Nanoparticles have long been sought as promising drug delivery system for cancer therapy, including liposomes, polymeric micelles, polymer-drug conjugates, dendrimers and polymeric nanoparticles. However, conventional nanoparticles would be specifically entrapped by the monocyte phagocytic system (MPS), and then quickly eliminated following intravenous administration, so the applications of nanoparticles are limited due to short circulation lifetime. Since long-circulation property is the prerequisite for nanoparticles reaching the target site of interest, the nanoparticle surface is usually modified by hydrophilic polymer materials such as PEG, to reduce plasma opsonization and MPS uptake. Furthermore, increased tumor specificity and cell internalization will improve the treatment efficacy and decrease the serious side effects for many cytotoxic antineoplastic drugs. Introducing the targeting ligands for interaction with specific tumor cells or tissues will offer major enhancement in cancer therapeutics via site specificity, reduction of multidrug resistance and improved delivery efficiency. This article will give an overview on the current state of long-circulating nanoparticles and describe their major advantages and potential pitfalls. Special emphasis is placed on the superiority of long-circulating nanoparticles used for tumor targeting.
Keywords: Nanoparticles, targeted drug delivery, long-circulating nanoparticles, cancer therapy
Current Nanoscience
Title: Long-circulating Targeted Nanoparticles for Cancer Therapy
Volume: 6 Issue: 4
Author(s): Yang Liu, Jin Sun, Jihong Han and Zhonggui He
Affiliation:
Keywords: Nanoparticles, targeted drug delivery, long-circulating nanoparticles, cancer therapy
Abstract: Nanoparticles have long been sought as promising drug delivery system for cancer therapy, including liposomes, polymeric micelles, polymer-drug conjugates, dendrimers and polymeric nanoparticles. However, conventional nanoparticles would be specifically entrapped by the monocyte phagocytic system (MPS), and then quickly eliminated following intravenous administration, so the applications of nanoparticles are limited due to short circulation lifetime. Since long-circulation property is the prerequisite for nanoparticles reaching the target site of interest, the nanoparticle surface is usually modified by hydrophilic polymer materials such as PEG, to reduce plasma opsonization and MPS uptake. Furthermore, increased tumor specificity and cell internalization will improve the treatment efficacy and decrease the serious side effects for many cytotoxic antineoplastic drugs. Introducing the targeting ligands for interaction with specific tumor cells or tissues will offer major enhancement in cancer therapeutics via site specificity, reduction of multidrug resistance and improved delivery efficiency. This article will give an overview on the current state of long-circulating nanoparticles and describe their major advantages and potential pitfalls. Special emphasis is placed on the superiority of long-circulating nanoparticles used for tumor targeting.
Export Options
About this article
Cite this article as:
Liu Yang, Sun Jin, Han Jihong and He Zhonggui, Long-circulating Targeted Nanoparticles for Cancer Therapy, Current Nanoscience 2010; 6 (4) . https://dx.doi.org/10.2174/157341310791658991
DOI https://dx.doi.org/10.2174/157341310791658991 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology Hypoxia and Fetal Heart Development
Current Molecular Medicine Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Delivery of Large Genomic DNA Inserts > 100 kb Using HSV-1 Amplicons
Current Gene Therapy Efficacy and Complications of Subcutaneous <i>versus</i> Conventional Cardioverter Defibrillators: A Systematic Review and Meta-analysis
Current Cardiology Reviews Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Red Cell Glycolytic Enzyme Disorders Caused by Mutations: An Update
Cardiovascular & Hematological Disorders-Drug Targets Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Efficacy of Enzyme Replacement Therapy in Fabry Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design